BioSenic publishes new evidence of beneficial effects of arsenic
trioxide treatment supporting clinical trial for systemic sclerosis
INSIDE INFORMATIONS
BioSenic publishes new evidence of
beneficial effects of arsenic trioxide treatment supporting
clinical trial for systemic sclerosis
Arsenic trioxide (ATO) therapeutic
potential to treat systemic sclerosis (SSc) is now confirmed in a
new preclinical model - Fra2- characterized by severe pulmonary
lesions
Mont-Saint-Guibert, Belgium, September
19, 2023, 7.00 am CEST – BIOSENIC
(Euronext Brussels and Paris: BIOS), the clinical-stage company
specializing in serious autoimmune and inflammatory diseases and
cell therapy, today announces the publication of data providing
additional key indications of its lead API (Active Pharmaceutical
Ingredient) arsenic trioxide (ATO) to treat systemic sclerosis
(SSc) in a peer-reviewed international journal.
The data are published in an article entitled
‘Arsenic trioxide demonstrates efficacy in a mouse model of
preclinical systemic sclerosis’ in the international journal
“Arthritis Research & Therapy”. This work studies the effects
of ATO on a preclinical auto-immune disease model, that develops
severe abnormal vascular remodeling of pulmonary arterioles and
nonspecific interstitial pneumonia-like lung disease, closely
resembling human systemic sclerosis (SSc)-associated pulmonary
hypertension.
Marked beneficial effects of ATO on skin and
lung fibrosis, vascular damage and scleroderma-like lesions have
been previously described by Kavian et al. (J Immunol 2012 May;
Arthritis Rheum 2012 Oct) in vitro and in SSc preclinical models,
at the Cochin Institute’s facilities in Paris, France. The new
data, in a third valuable preclinical model, show a significant
reduction in inflammatory infiltration and a strong improvement in
vascular remodeling, mediated by an immune status improvement,
particularly involving T-cells. These findings represent a
substantial advancement in understanding of the complex interplay
between inflammation-driven fibrosis and the pathophysiology of
SSc. These results give ground to the proposed clinical relevance
of ATO treatment in SSc, and more generally in autoimmune
pathologies, where lung is often impacted by fibrosis and vascular
remodeling.
In oncology, ATO is now recognized as a
first-line treatment for acute promyelocytic leukaemia, with
demonstrated safety and long-term remission. BioSenic had recently
further demonstrated the safety and efficacy of ATO treatment in
successful clinical programs targeting chronic Graft-versus-Host
Disease, in a phase 2 and Systemic Lupus Erythematosus (SLE), in a
phase 2a trial. BioSenic believes that the clinical data it has
helped to generate over the past decade, together with its ongoing
efforts to understand the cellular pathways that are controlled by
ATO administration at the right dose and time, now allow for
further expansion of clinical trials targets. This applies to new
indications in autoimmunity and inflammatory diseases. This is a
reason why BioSenic specifically selected SSc for a systematic
clinical approach to testing ATO as a novel first-in-class
therapy.
François Rieger, PhD, Chairman and CEO,
BioSenic said: "BioSenic is now focusing on the final
preparations for its phase 3 trial with ATO targeting chronic
Graft-versus-Host Disease, one of the most common complications
affecting survival of allogeneic hematopoietic stem cell
transplantation patients. It is also essential that BioSenic
continues to pave the way for clinical progression of its ATO
programs to treat systemic lupus erythematosus and systemic
sclerosis. These new pre-clinical data add to the raft of in vitro
and in vivo experimental data generated by BioSenic, by the
scientific community and across the industry, supporting the
potential of arsenic salt medication in correcting the
pathophysiological parameters of the immune system gone awry in a
number of autoimmune diseases. These results demonstrate the
potential of ATO on the cellular characteristics of damaged organs,
with chronic and aggravating functional abnormalities. This will
provide invaluable knowledge for BioSenic’s ATO application and
formulation for the ongoing clinical development, and further
contribute towards the future success of ATO’s late-stage clinical
development. Compounded observations, both widely published and
collected in various international studies, fully justify the
initiation of trials on SSc patients, in need of new and decisive
medications, other than existing palliative ones. The hope for
success is high and BioSenic is working hard in translating the
present fundamental results into real therapeutic advances with the
necessary help of available international funding.”
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from: (i)
the arsenic trioxide (ATO) platform (with key target indications
including Graft-versus-Host Disease (GvHD), systemic lupus
erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the
development of innovative products to meet unmet needs in
orthopedics.Following a reverse merger in October 2022, BioSenic
combined a strategic positionings and strengths to use, separately
and combined, an entirely new arsenal of various anti-inflammatory
and anti-autoimmune formulations using the immunomodulatory
properties of ATO/oral ATO (OATO) with its innovative cell therapy
platform and strong IP for tissue repair protection.BioSenic is
based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert,
Belgium. Further information is available at
http://www.biosenic.com.
About BioSenic technology
platforms
BioSenic’s technology is based on two main
platforms:
- The ATO platform, which has been successfully developed, has
immunomodulatory properties with fundamental effects on the
activated cells of the immune system. The first effect is the
increase of the cell oxidative stress in activated B, T and other
cells of the innate/adaptative immune system to the point they will
enter a cell death program (apoptosis) and be eliminated. The
second effect is potent immunomodulatory properties on several
cytokines involved in inflammatory or autoimmune cell pathways,
with return to homeostasis. One direct application is its use in
onco-immunology to treat GvHD (Graft-versus-Host Disease) in its
chronic, established stage. cGvHD is one of the most common and
clinically significant complications affecting long-term survival
of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
cGvHD is primarily mediated by the transplanted immune cells that
can lead to severe multiorgan damage. BioSenic has been successful
in a Phase 2 trial with its intravenous formulation, which has
orphan drug designation status by FDA and EMA. The Company is
heading towards an international Phase 3 confirmatory study, with
its new, IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae and the gastrointestinal tract) in an early Phase 2a study.
Systemic sclerosis is also part of the clinical pipeline of
BioSenic. This serious chronic disease badly affects skin, lungs or
vascularization, and has no actual current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a Phase 2 clinical protocol.
- The allogeneic cell and gene therapy platform developed by
BioSenic, with differentiated bone marrow sourced Mesenchymal
Stromal Cells (MSCs), which can be stored at the point of use in
hospitals. ALLOB represents a unique and proprietary approach to
organ repair and specifically to bone regeneration, by turning
undifferentiated stromal cells from healthy donors into
bone-forming cells on the site of injury. ALLOB has recently been
evaluated in a randomized, double-blind, placebo-controlled Phase
2b study in patients with high-risk tibial fractures, using its
optimized production process, after a successful first safety and
efficacy study (Phase 1/2a) on fractured long bones, with
late-delayed union. However, in June 2023, BioSenic decided to
suspend its interventional trial on fracture healing using ALLOB,
following negative results obtained for the primary endpoint in
this exploratory Phase 2b clinical trial, interpreted as a failure
of a too early cell injection, just after fracture. BioSenic is now
focusing on determining the best time to optimise the efficacy of
ALLOB (choice between early or late treatment).
Note: Biosenic has reevaluated a previous
important and years-long clinical development program. In March
2023, after the clinical identification of distinct OA subtypes,
BioSenic delivered a new post-hoc analysis of its Phase 3 JTA-004
trial on knee OA, demonstrating positive action on the most
severely affected patient subpopulation. This new post-hoc analysis
drastically changes the therapeutic profile of the combined
components and allows for better patient targeting in future
clinical developments. This leads to a next generation of JTA,
off-the-shelf enhanced viscosupplement to treat knee osteoarthritis
(OA), made of a unique combination of mammalian plasma proteins,
derivatives of hyaluronic acid (a natural component of synovial
fluid in the knee) and a third active component. JTA or some
derivatives are intended to provide effective lubrication and
protection to the cartilage of the arthritic joint and to alleviate
osteoarthritic (OA) pain and inflammation. The company, will
nevertheless focus its present R&D and clinical activities on a
selective, accelerated development of its autoimmune (ATO/OATO)
platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect the Company or, as appropriate, the Company
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
BioSenic publishes
new evidence of beneficial effects of arsenic
trioxide treatment supporting
clinical trial for systemic
sclerosis
Arsenic trioxide (ATO)
therapeutic potential to
treat systemic sclerosis
(SSc)
is now confirmed in
a new preclinical model
- Fra2- characterized
by severe pulmonary
lesions
Mont-Saint-Guibert, Belgium,
September 19,
2023,
7.00
am CEST
– BIOSENIC (Euronext Brussels and Paris:
BIOS), the clinical-stage company specializing in serious
autoimmune and inflammatory diseases and cell therapy, today
announces the publication of data providing additional key
indications of its lead API (Active Pharmaceutical Ingredient)
arsenic trioxide (ATO) to treat systemic sclerosis (SSc) in a
peer-reviewed international journal.
The data are published in an article entitled
‘Arsenic trioxide demonstrates efficacy in a mouse model of
preclinical systemic sclerosis’ in the international journal
“Arthritis Research & Therapy”. This work studies the effects
of ATO on a preclinical auto-immune disease model, that develops
severe abnormal vascular remodeling of pulmonary arterioles and
nonspecific interstitial pneumonia-like lung disease, closely
resembling human systemic sclerosis (SSc)-associated pulmonary
hypertension.
Marked beneficial effects of ATO on skin and
lung fibrosis, vascular damage and scleroderma-like lesions have
been previously described by Kavian et al. (J Immunol 2012 May;
Arthritis Rheum 2012 Oct) in vitro and in SSc preclinical models,
at the Cochin Institute’s facilities in Paris, France. The new
data, in a third valuable preclinical model, show a significant
reduction in inflammatory infiltration and a strong improvement in
vascular remodeling, mediated by an immune status improvement,
particularly involving T-cells. These findings represent a
substantial advancement in understanding of the complex interplay
between inflammation-driven fibrosis and the pathophysiology of
SSc. These results give ground to the proposed clinical relevance
of ATO treatment in SSc, and more generally in autoimmune
pathologies, where lung is often impacted by fibrosis and vascular
remodeling.
In oncology, ATO is now recognized as a
first-line treatment for acute promyelocytic leukaemia, with
demonstrated safety and long-term remission. BioSenic had recently
further demonstrated the safety and efficacy of ATO treatment in
successful clinical programs targeting chronic Graft-versus-Host
Disease, in a phase 2 and Systemic Lupus Erythematosus (SLE), in a
phase 2a trial. BioSenic believes that the clinical data it has
helped to generate over the past decade, together with its ongoing
efforts to understand the cellular pathways that are controlled by
ATO administration at the right dose and time, now allow for
further expansion of clinical trials targets. This applies to new
indications in autoimmunity and inflammatory diseases. This is a
reason why BioSenic specifically selected SSc for a systematic
clinical approach to testing ATO as a novel first-in-class
therapy.
François Rieger, PhD, Chairman and CEO,
BioSenic said: "BioSenic is now focusing on the final
preparations for its phase 3 trial with ATO targeting chronic
Graft-versus-Host Disease, one of the most common complications
affecting survival of allogeneic hematopoietic stem cell
transplantation patients. It is also essential that BioSenic
continues to pave the way for clinical progression of its ATO
programs to treat systemic lupus erythematosus and systemic
sclerosis. These new pre-clinical data add to the raft of in vitro
and in vivo experimental data generated by BioSenic, by the
scientific community and across the industry, supporting the
potential of arsenic salt medication in correcting the
pathophysiological parameters of the immune system gone awry in a
number of autoimmune diseases. These results demonstrate the
potential of ATO on the cellular characteristics of damaged organs,
with chronic and aggravating functional abnormalities. This will
provide invaluable knowledge for BioSenic’s ATO application and
formulation for the ongoing clinical development, and further
contribute towards the future success of ATO’s late-stage clinical
development. Compounded observations, both widely published and
collected in various international studies, fully justify the
initiation of trials on SSc patients, in need of new and decisive
medications, other than existing palliative ones. The hope for
success is high and BioSenic is working hard in translating the
present fundamental results into real therapeutic advances with the
necessary help of available international funding.”
About
BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from: (i)
the arsenic trioxide (ATO) platform (with key target indications
including Graft-versus-Host Disease (GvHD), systemic lupus
erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the
development of innovative products to meet unmet needs in
orthopedics.Following a reverse merger in October 2022, BioSenic
combined a strategic positionings and strengths to use, separately
and combined, an entirely new arsenal of various anti-inflammatory
and anti-autoimmune formulations using the immunomodulatory
properties of ATO/oral ATO (OATO) with its innovative cell therapy
platform and strong IP for tissue repair protection.BioSenic is
based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert,
Belgium. Further information is available at
http://www.biosenic.com.
About BioSenic technology
platforms
BioSenic’s technology is based on two main
platforms:1) The ATO platform, which has been
successfully developed, has immunomodulatory properties with
fundamental effects on the activated cells of the immune system.
The first effect is the increase of the cell oxidative stress in
activated B, T and other cells of the innate/adaptative immune
system to the point they will enter a cell death program
(apoptosis) and be eliminated. The second effect is potent
immunomodulatory properties on several cytokines involved in
inflammatory or autoimmune cell pathways, with return to
homeostasis. One direct application is its use in onco-immunology
to treat GvHD (Graft-versus-Host Disease) in its chronic,
established stage. cGvHD is one of the most common and clinically
significant complications affecting long-term survival of
allogeneic hematopoietic stem cell transplantation (allo-HSCT).
cGvHD is primarily mediated by the transplanted immune cells that
can lead to severe multiorgan damage. BioSenic has been successful
in a Phase 2 trial with its intravenous formulation, which has
orphan drug designation status by FDA and EMA. The Company is
heading towards an international Phase 3 confirmatory study, with
its new, IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae and the gastrointestinal tract) in an early Phase 2a study.
Systemic sclerosis is also part of the clinical pipeline of
BioSenic. This serious chronic disease badly affects skin, lungs or
vascularization, and has no actual current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a Phase 2 clinical protocol.
2) The allogeneic cell and gene therapy platform
developed by BioSenic, with differentiated bone marrow sourced
Mesenchymal Stromal Cells (MSCs), which can be stored at the point
of use in hospitals. ALLOB represents a unique and proprietary
approach to organ repair and specifically to bone regeneration, by
turning undifferentiated stromal cells from healthy donors into
bone-forming cells on the site of injury. ALLOB has recently been
evaluated in a randomized, double-blind, placebo-controlled Phase
2b study in patients with high-risk tibial fractures, using its
optimized production process, after a successful first safety and
efficacy study (Phase 1/2a) on fractured long bones, with
late-delayed union. However, in June 2023, BioSenic decided to
suspend its interventional trial on fracture healing using ALLOB,
following negative results obtained for the primary endpoint in
this exploratory Phase 2b clinical trial, interpreted as a failure
of a too early cell injection, just after fracture. BioSenic is now
focusing on determining the best time to optimise the efficacy of
ALLOB (choice between early or late treatment).Note: Biosenic has
reevaluated a previous important and years-long clinical
development program. In March 2023, after the clinical
identification of distinct OA subtypes, BioSenic delivered a new
post-hoc analysis of its Phase 3 JTA-004 trial on knee OA,
demonstrating positive action on the most severely affected patient
subpopulation. This new post-hoc analysis drastically changes the
therapeutic profile of the combined components and allows for
better patient targeting in future clinical developments. This
leads to a next generation of JTA, off-the-shelf enhanced
viscosupplement to treat knee osteoarthritis (OA), made of a unique
combination of mammalian plasma proteins, derivatives of hyaluronic
acid (a natural component of synovial fluid in the knee) and a
third active component. JTA or some derivatives are intended to
provide effective lubrication and protection to the cartilage of
the arthritic joint and to alleviate osteoarthritic (OA) pain and
inflammation. The company, will nevertheless focus its present
R&D and clinical activities on a selective, accelerated
development of its autoimmune (ATO/OATO) platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor
Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Biosenic (LSE:0R55)
Historical Stock Chart
From May 2024 to Jun 2024
Biosenic (LSE:0R55)
Historical Stock Chart
From Jun 2023 to Jun 2024